All In Biotech

Drug Trial Radar · NCT05559125

A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects

An Open-label, Single-ascending Dose Phase I Study to Evaluate the Safety and Tolerability of STSA-1002 Combined With STSA-1005 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: May 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

50

Actual

Start

Nov 8, 2022

Primary completion

Mar 26, 2024

Study completion Mar 26, 2024

Sponsor

Sponsor type
Industry
First posted
Sep 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An open-label, single-ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of STSA-1002 combined with STSA-1005 in healthy subjects.

Conditions

  • Healthy Subject

Interventions

  • STSA-1002 InjectionDrug

    Intravenous injection

  • STSA-1005 InjectionDrug

    Intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram、Vital Signs And Physical Examination Abnormalities.Time frame: 56 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital Of Xingtai Medical College

    Xingtai, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.